Amivantamab

Multispecific antibody

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Colorectal Cancer · Phase 3 · investigational in the USHead and Neck Squamous Cell Carcinoma · Phase 3 · investigational in the US

Also approved (2)
JP
  • Treatment of unresectable advanced or recurrent epidermal growth factor receptor (EGFR) gene exon 20 insertion mutation-positive non-small cell lung cancer
Product first approved 2024PMDA
EU
  • Conditional MA: EGFR exon 20 insertion NSCLC after platinum-based therapy (EPAR now lists four NSCLC indications)
Product first approved 2021EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (7)
Colorectal Cancer
Head and Neck Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
NCT05388669 · Janssen Research & Development, LLC
2022-08-05 – 2027-06-30 · Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
Phase 2 (23)
Colorectal Cancer
NCT05845450 · Gruppo Oncologico del Nord-Ovest
2023-05-11 – 2028-05 · Colorectal Cancer, Resectable Colorectal Carcinoma
What this study did
Head and Neck Squamous Cell Carcinoma
NCT07062354 · SWOG Cancer Research Network
2026-03-25 – 2029-10 · Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT06120140 · Janssen Research & Development, LLC
2024-02-16 – 2030-06-30 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT07392658 · Fondazione Ricerca Traslazionale
2025-12-02 – 2028-10 · Metastatic NSCLC - Non-Small Cell Lung Cancer
What this study did
NCT05498428 · Janssen Research & Development, LLC
2022-11-11 – 2028-08-18 · Carcinoma, Non-small-Cell Lung
What this study did
NCT06116682 · SWOG Cancer Research Network
2024-11-19 – 2028-05-31 · Lung Non-Small Cell Carcinoma
What this study did
NCT07586202 · Janssen Research & Development, LLC
2026-07-28 – 2028-04-03 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT05801029 · AstraZeneca
2023-07-18 – 2027-10-01 · Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT05663866 · Janssen Research & Development, LLC
2023-05-18 – 2027-09-30 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT05601973 · ETOP IBCSG Partners Foundation
2023-03-27 – 2027-04 · Non Small Cell Lung Cancer
What this study did
NCT05299125 · Latin American Cooperative Oncology Group
2023-05-24 – 2025-11-21 · Metastatic Non-small Cell Lung Cancers
What this study did
Other / comorbidity
NCT07808359 · Latin American Cooperative Oncology Group
2026-11 – 2029-11 · Penile Squamous Cell Carcinoma, Metastatic Penile Squamous Cell Carcinoma
What this study did
NCT07042295 · National Cancer Institute (NCI)
2026-03-23 – 2029-02-28 · Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
What this study did
NCT05074940 · Trisha Wise-Draper
2022-08-05 – 2028-08-05 · Salivary Gland Cancer
What this study did
NCT03767075 · Vall d'Hebron Institute of Oncology
2018-12-10 – 2027-11 · Advanced Solid Tumor
What this study did
NCT05117931 · Memorial Sloan Kettering Cancer Center
2021-12-02 – 2026-11 · Esophagogastric Cancer
What this study did
NCT05653427 · Janssen Research & Development, LLC
2022-12-08 – 2023-10-10 · Carcinoma, Hepatocellular
What this study did
NCT04945733 · Janssen Pharmaceutical K.K.
2021-08-30 – 2023-07-03 · Stomach Neoplasms, Esophageal Neoplasms
What this study did
Phase 1/2 (9)
Colorectal Cancer
NCT05379595 · Janssen Research & Development, LLC
2022-07-29 – 2031-05-11 · Advanced or Metastatic Colorectal Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT06385080 · Janssen Research & Development, LLC
2024-04-22 – 2033-07-28 · Squamous Cell Carcinoma of Head and Neck
What this study did
Non-Small Cell Lung Cancer
NCT07227025 · Janssen Research & Development, LLC
2026-03-03 – 2029-04-30 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT07744529 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-05-28 – 2028-05-28 · Leptomeningeal Metastasis From Lung Cancer
What this study did
NCT05845671 · University of Colorado, Denver
2023-07-17 – 2028-01 · Lung Cancer, Non Small Cell Lung Cancer
What this study did
NCT06083857 · M.D. Anderson Cancer Center
2024-06-18 – 2027-12-31 · Non-small Cell Lung Cancer
What this study did
NCT05908734 · Janssen Research & Development, LLC
2023-05-18 – 2027-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT05488314 · Janssen Research & Development, LLC
2022-12-13 – 2027-05-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT06532032 · Janssen Research & Development, LLC
2024-07-23 – 2026-05-14 · Carcinoma, Non-Small-Cell Lung
What this study did
Phase 1 (9)
Head and Neck Squamous Cell Carcinoma
NCT05395052 · Fate Therapeutics
2022-05-31 – 2023-08-11 · Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07798921 · Yonsei University
2026-09-28 – 2030-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04077463 · Janssen Research & Development, LLC
2019-09-04 – 2028-03-27 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT06816992 · ORIC Pharmaceuticals
2025-02-27 – 2027-12 · Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC
What this study did
Other / comorbidity
NCT07107230 · Janssen Research & Development, LLC
2025-07-15 – 2028-04-24 · Advanced Stage Solid Tumors
What this study did
NCT06632236 · Institute of Cancer Research, United Kingdom
2024-10-09 – 2027-07-01 · Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Glioblastoma Multiforme (GBM)
What this study did
NCT04606381 · Janssen Research & Development, LLC
2020-11-10 – 2027-04-01 · Neoplasms
What this study did
NCT06507306 · Kumquat Biosciences Inc.
2024-06-03 – 2027-01-31 · Solid Tumor, Adult
What this study did
Phase 4 (1)
Non-Small Cell Lung Cancer
NCT07469488 · Shanghai Pulmonary Hospital, Shanghai, China
2026-04-30 – 2029-12-31 · NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism), Rash Due to Epidermal Growth Factor Receptor Inhibitors, Infusion Reaction
What this study did
Early phase / not applicable (1)
Non-Small Cell Lung Cancer
NCT06247826 · Groupe Francais De Pneumo-Cancerologie
2024-01-15 – 2026-07-30 · Non-small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2/3 (1)
Non-Small Cell Lung Cancer

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Colorectal Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Amivantamab: this drugPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
NCT02314819: Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis)
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Weak signal
NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
BecotatugPhase 3Monoclonal antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890Phase 3Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 3Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 2/3PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
IBI305Phase 2Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
SirexatamabPhase 2Monoclonal antibodyDKK1 (Dickkopf-1)not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
NC410
Phase 1/2(overall)
Protein / enzyme therapeuticCollagen (LAIR-1 ligands)not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T Cell
Phase 1(overall)
Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
PI3Kalpha Precision Therapy
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(34 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Amivantamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (1)
Phase 2Esophagogastric CancerActive not recruiting
Est. primary completion 2026-11 · NCT05117931 · CT.gov ↗
What to watch
December 2026 (3)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT06816992 · CT.gov ↗
What to watch
Phase 1Solid Tumor, AdultActive not recruiting
Est. primary completion 2026-12-31 · NCT06507306 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT02609776 · CT.gov ↗
What to watch
2027 (16)
January 2027 (1)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-31 · NCT05908734 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-02-12 · NCT04077463 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2027-04-27 · NCT05379595 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-04-28 · NCT05488314 · CT.gov ↗
What to watch
May 2027 (4)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-05 · NCT06855849 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-05 · NCT05845450 · CT.gov ↗
What to watch
Phase 2Advanced Solid TumorRecruiting
Est. primary completion 2027-05 · NCT03767075 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05-31 · NCT06120140 · CT.gov ↗
What to watch
July 2027 (2)
Phase 1Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant …Active not recruiting
Est. primary completion 2027-07-01 · NCT06632236 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-07-31 · NCT06784791 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-17 · NCT05498428 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-10 · NCT07392658 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10-01 · NCT05801029 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1Advanced Stage Solid TumorsRecruiting
Est. primary completion 2027-11-18 · NCT07107230 · CT.gov ↗
What to watch
December 2027 (2)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2027-12-15 · NCT06750094 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT06083857 · CT.gov ↗
What to watch
2028 (7)
March 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-02 · NCT07586202 · CT.gov ↗
What to watch
May 2028 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-05-28 · NCT07744529 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-05-31 · NCT06116682 · CT.gov ↗
What to watch
June 2028 (1)
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-06-01 · NCT07798921 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Head and Neck Squamous Cell CarcinomaEnrolling by invitation
Est. primary completion 2028-10 · NCT07062354 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-11-30 · NCT07227025 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2028-12-15 · NCT06662786 · CT.gov ↗
What to watch
2029 (5)
February 2029 (2)
Phase 2Penile Squamous Cell Carcinoma, Metastatic Penile Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-02 · NCT07808359 · CT.gov ↗
What to watch
Phase 2Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-02-28 · NCT07042295 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-05-23 · NCT06667076 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-06-18 · NCT07276399 · CT.gov ↗
What to watch
August 2029 (1)
Phase 4Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-08-31 · NCT07469488 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-01-31 · NCT07507188 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 1/2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2032-12-27 · NCT06385080 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 February 2026ApprovalEC approves subcutaneous amivantamab Q3W and Q4W dosing
EU, EMA · Source ↗
17 February 2026ApprovalFDA approves monthly dosing schedule for RYBREVANT FASPRO
US, FDA · Source ↗